SCHEMBL16065614

SCHEMBL16065614

Cc1cc2c(C)c(Oc3nc(Nc4cc(C5CC5)[nH]n4)cc(N4CCN(C)CC4)n3)ccc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.51
IGF1R P08069 8/20 0.49
AURKA O14965 2/20 0.49
NTRK1 P04629 2/20 0.49
TBK1 Q9UHD2 2/20 0.48
PIK3C3 Q8NEB9 1/20 0.48
RET P07949 2/20 0.46
BMPR1B O00238 1/20 0.45
PLK4 O00444 1/20 0.45
EPHB6 O15197 1/20 0.45
STK10 O94804 1/20 0.45
PRKD3 O94806 1/20 0.45
PAK4 O96013 1/20 0.45
ABL1 P00519 1/20 0.45
INSR P06213 1/20 0.45
LCK P06239 1/20 0.45
FYN P06241 1/20 0.45
YES1 P07947 1/20 0.45
LYN P07948 1/20 0.45
HCK P08631 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15704847 0.97 AURKA (0.51) EGFRIGF1RAURKANTRK1TBK1
SCHEMBL16065556 0.92 EGFR (0.50) EGFRIGF1RAURKANTRK1TBK1
SCHEMBL15704875 0.92 EGFR (0.50) EGFRIGF1RAURKANTRK1TBK1
SCHEMBL15704979 0.90 EGFR (0.63) EGFRAURKANTRK1TBK1PIK3C3
SCHEMBL17175714 0.89 AURKA (0.50) EGFRIGF1RAURKANTRK1TBK1
SCHEMBL17175998 0.89 AURKA (0.50) EGFRIGF1RAURKANTRK1TBK1
SCHEMBL16065639 0.87 EGFR (0.53) EGFRIGF1RAURKATBK1PIK3C3
SCHEMBL15704981 0.86 EGFR (0.52) EGFRAURKANTRK1TBK1PIK3C3
SCHEMBL15704793 0.85 PAK4 (0.42) EGFRIGF1RAURKANTRK1TBK1
SCHEMBL17175543 0.85 IGF1R (0.42) EGFRIGF1RAURKANTRK1TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10245261-B2 Substituted indol-5-ol derivatives and their therapeutic applications NANTBIO, INC. (US) 2019-04-02 US disclosed
US-20170189400-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS NANTBIO, INC. 2017-07-06 US disclosed
US-20170088544-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIO, INC. 2017-03-30 US disclosed
US-9550760-B2 Substituted indol-5-ol derivatives and their therapeutic applications NANTBIOSCIENCE, INC. (US) 2017-01-24 US disclosed
US-9458137-B2 Substituted indol-5-ol derivatives and their therapeutical applications NANTBIOSCIENCE, INC. (US) 2016-10-04 US disclosed
US-20160016945-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS NANTBIO, INC. 2016-01-21 US disclosed
US-20150291564-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. (US) 2015-10-15 US disclosed
WO-2014145403-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS NANTBIO, INC. (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189400-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS GRK5, GRK3, CDK5 EGFR 668/4885IGF1R 296/4885AURKA 796/4885
US-20170088544-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS GRK5, GRK3, MTMR1 EGFR 658/4885IGF1R 217/4885AURKA 1063/4885
US-10245261-B2 Substituted indol-5-ol derivatives and their therapeutic applications GRK5, GRK3, CDK5 EGFR 668/4885IGF1R 296/4885AURKA 796/4885
US-20150291564-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS GRK5, GRK3, MTMR1 EGFR 658/4885IGF1R 217/4885AURKA 1063/4885
US-20160016945-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS GRK5, GRK3, CDK5 EGFR 668/4885IGF1R 296/4885AURKA 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.